Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

@article{Siris2005SkeletalEO,
  title={Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study},
  author={E. Siris and S. T. Harris and R. Eastell and J. Zanchetta and S. Goemaere and A. Diez-Perez and J. Stock and Jingli Song and Y. Qu and P. Kulkarni and S. Siddhanti and M. Wong and S. Cummings},
  journal={Journal of Bone and Mineral Research},
  year={2005},
  volume={20}
}
In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE had limitations for assessing fracture risk. In a subset of 386 women, 7 years of raloxifene treatment significantly increased lumbar spine and femoral neck BMD compared from the baseline of MORE. 
Not all SERMs are created equal: chapter 2.
Long-term raloxifene for postmenopausal osteoporosis
Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
  • P. Sambrook
  • Medicine
  • Best practice & research. Clinical rheumatology
  • 2005
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension
  • K. Ensrud, E. Barrett-Connor, +9 authors D. Black
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2004
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
...
1
2
3
4
5
...